Business Wire

VALBIOTIS Announces Positive Results From the Phase IIA Clinical Study of VALEDIA®, Now the First Product Proven Effective in People With Prediabetes

Share

Regulatory News:

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/PME eligible), Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced positive results (topline data) for the Phase IIA study1 of VALEDIA® (active substance: TOTUM-63), which evaluated this product's efficacy in a prediabetic population, compared to placebo. In this population, VALEDIA® significantly reduced fasting and post-prandial blood glucose levels, the two main risk factors for type 2 diabetes and the primary and secondary endpoints of the study, respectively. VALEDIA® also significantly reduced body weight and waist circumference. Thanks to these results, VALEDIA® is the first clinically validated product designed for prediabetic people, to reduce several risk factors for type 2 diabetes. These results enable the concomitant launch of the last two Phase IIB clinical studies (REVERSE-IT and PREVENT-IT), to obtain the first health claims for the risk reduction of type 2 diabetes in Europe and North America. This regulatory process does not require a Phase III study. Commercialization is planned for 2021, as previously announced.

Professor Jean-Marie BARD, Hospital Practitioner and Professor of Fundamental and Clinical Biochemistry at the University of Nantes, scientific expert for the study comments, "The reduction of fasting blood glucose and blood glucose 2 hours after a glucose intake is a new advance for prediabetics. These results show the impact of VALEDIA® on metabolism, with even a decrease in body weight and waist circumference, usually hard to demonstrate in clinical studies. With such data, VALEDIA® proves its efficacy to reduce type 2 diabetes risk factors.“

Murielle CAZAUBIEL, member of the board and Director of Development and Medical Affairs at VALBIOTIS, adds: "VALEDIA® was designed to carry out multiple actions on several metabolic targets, thanks to an original plant-based composition. This innovation has had clinical success in people with prediabetes: we now know that VALEDIA® acts on risk factors for type 2 diabetes. This study is a great success, and we'd like to express our thanks to all the volunteers who participated."

Main results of the VALEDIA® Phase IIA clinical study in prediabetic people

This multicenter study, conducted in Europe, evaluated TOTUM-63, the active ingredient of VALEDIA®, in prediabetic people for 6 months. It was a randomized, double-blind, placebo-controlled study. Included subjects received a daily dose of 5 grams of VALEDIA® while the control group received 5 grams of the placebo. Dietary habits and physical activity levels remained unchanged in both groups during the study. The inclusion criteria were strict to ensure the robustness of the study: the subjects had to have moderate hyperglycemia, hyperglycemia 2 hours after glucose dose (OGTT, Oral Glucose Tolerance Test), abdominal obesity and hypertriglyceridemia. With such characteristics, the included subjects were particularly at risk of fast and pejorative evolution. Analyses were conducted on 51 subjects, 13 in the placebo group and 38 in the VALEDIA® group, according to the unbalanced study design.

Main characteristics of the study population:
Age:
57.1 years old
Gender: 35 women and 16 men
Body Mass Index: 31.3 Kg/m2
Fasting glycemia: 1.26 g/L
2h-glycemia (OGTT): 1.85 g/L
Blood triglycerides: 1.78 g/L

• Main criterion met:

VALEDIA ® significantly reduced fasting blood glucose levels, compared to the placebo, after 6 months (p<0.05).

 

Fasting glycemia (g/L)

 

6 months variation (g/L)

Variation VALEDIA®
vs placebo 2

Placebo (n=13 subjects)

+ 0.09 (± 0.04)

- 9.3%

VALEDIA® (n=38 subjects)

- 0.04 (± 0.02)

 

Mean values (± SEM)

 

Moderate fasting hyperglycemia is the main risk factor for type 2 diabetes identified in people with prediabetes. With these results, VALBIOTIS defines the reduction of fasting blood glucose levels as the primary endpoint of the last two clinical studies that will be used to support requests for health claims in Europe, the United States and Canada.

• Secondary criteria met:

VALEDIA® significantly reduces blood glucose levels after 2 hours (post-prandial blood glucose), the second risk factor for type 2 diabetes, compared to the placebo (p<0.05).

 

2 hours OGTT glycemia (g/L)

 

6 months variation (g/L)

Variation VALEDIA®
vs placebo 2

Placebo (n=13 subjects)

+ 0.32 (± 0.17)

- 22.5%

VALEDIA® (n=38 subjects)

- 0.02 (± 0.07)

 

Mean values (± SEM)

 

VALEDIA® significantly reduced two anthropometric parameters, compared to the placebo: body weight (p< 0.05) and waist circumference (p< 0.001).

 

Body weight (Kg)

 

6 months variation (g/L)

Variation VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 1.83 (± 0.57)

- 1.9 Kg

VALEDIA® (n=38 subjects)

- 0.07 (± 0.42)

 

Mean values (± SEM)

 

 

Waist circumference (cm)

 

6 months variation (cm)

Variation VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 2.81 (± 0.65)

- 4.48 cm

VALEDIA® (n=38 subjects)

- 1.67 (± 0.73)

 

Mean values (± SEM)

 

Furthermore, safety data confirm that this plant-based product achieves perfect tolerance.

For Sébastien PELTIER, CEO of VALBIOTIS "The results of this clinical Phase IIA study exceed our expectations. They demonstrate that TOTUM-63, the active substance of VALEDIA®, reduces the two main risk factors for type 2 diabetes in people with prediabetes. This success validates the concomitant launch of the last two clinical studies for VALEDIA® to obtain the first health claims for the risk reduction of type 2 diabetes, in Europe and in North America. This major milestone strengthens our discussions with potential partners for marketing VALEDIA®. This is a critical milestone for VALBIOTIS: we have now scientifically validated in humans the efficacy of our new plant-based approach to prevent metabolic diseases. We would like to thank our teams, partners and shareholders. "

About TOTUM-63, the active substance of VALEDIA®

Prediabetes is an increasingly prevalent public health problem worldwide and recognized by international organizations such as the WHO, the American Diabetes Association and the International Diabetes Federation. Without effective treatment, 70% to 90% of prediabetic patients will develop type 2 diabetes.

VALEDIA® is the first clinically validated product specifically designed to help prediabetics to reduce the risk of developing type 2 diabetes. VALEDIA® is the only product that contains the active substance TOTUM-63, a unique and patented combination of 5 plant extracts that act synergistically to target the physiopathological mechanisms of type 2 diabetes.

TOTUM-63 has already shown perfect tolerance and safety during a Phase I/II clinical study conducted in healthy volunteers. The results of the first international randomized placebo-controlled study showed that TOTUM-63 reduces fasting blood glucose levels and blood glucose after 2 hours, two risk factors for type 2 diabetes in people with prediabetes.

All the results from the Phase IIA study, as well as all key company information are available in the updated corporate presentation, available here: www.valbiotis.com/en/documents/

ABOUT VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS:
http://valbiotis.com/

Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL

Disclaimer

This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 5 April 2017 (application number I.17-012), as well as in the 2018 annual financial report, filed with AMF on 8 March 2019. This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.

1 ID-RCB Number: 2016-A00484-47
2 Difference of the means of individual variations expressed in %.
3 Difference of the means of individual variations.

Contact information

VALBIOTIS 
CORPORATE COMMUNICATION 
Carole Rocher / 
Marc Delaunay 
+33 5 46 28 62 58 
medias@valbiotis.com

FINANCIAL COMMUNICATION 
ACTIFIN 
Stéphane Ruiz 
+33 1 56 88 11 14 
sruiz@actifin.fr

MEDIA RELATIONS 
MADIS PHILEO 
Guillaume De Chamisso 
+33 6 85 91 32 56 
guillaume.dechamisso@madisphileo.com

UNITED STATES 
SOLEBURY TROUT 
Rebecca John / Patrick Till 
+1 646 378 2935 
rjohn@troutgroup.com 
ptill@troutgroup.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Social Football Summit 2019 to Take Place in Rome in Partnership With Lega Serie A19.11.2019 12:02:00 CETPress release

Debates, meetings and networking dedicated to digital marketing and innovation in the world of football, are part of the programme of the second edition of the Social Football Summit scheduled for Wednesday 20 and Thursday 21/11/2019 at the Stadio Olympico in Rome (ITA). The event, organised by the start up "Social Media Soccer" and the digital company "Go Project", in partnership with the Lega Serie A, will feature 75 speakers during some thirty conferences, debates and other formats divided into two main themes: • The first is dedicated to the most significant and original initiatives in digital marketing and fan engagement. • The second is dedicated to digital transformation processes, sports technology, eSports, blockchain and other innovative projects. "The Lega Serie A is very aware of the need to exploit all the new digital marketing tools in order to be a leader in Italy and around the world. The market on which we want to focus strongly is the eSports market, which is now full

XPRIZE Announces New $10 Million Competition to Preserve Rainforests Across the Globe19.11.2019 12:00:00 CETPress release

Today, XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially launched the $10M Rainforest XPRIZE. Registration is now open for teams interested in participating in the four-year global competition that calls on innovators to create technology capable of identifying and cataloging rainforest biodiversity and develop insights that may lead to a new bioeconomy through standing forests. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005397/en/ (Graphic: Business Wire) Rainforests remain undervalued, which has led to their rapid depletion over the past two decades. Having once covered 14% of the earth’s land surface, rainforests now cover a mere 6% of the planet, according to National Geographic. Specifically, the recent acceleration of the Amazon’s deforestation, due in part to illegal logging and mining as well as inefficient agricultural expansion, ha

Desktop Metal Launches World’s First Metal Binder Jetting System Designed for Machine Shops19.11.2019 10:45:00 CETPress release

Desktop Metal, the company committed to making 3D printing accessible to manufacturers and engineers, today announced the launch of Shop System™, the world’s first metal binder jetting system designed for machine shops and metal job shops. For the first time, shop owners can leverage affordable, high-quality binder jetting technology to print end-use metal parts with unparalleled speed, print quality, and productivity. The system was unveiled during Formnext 2019, a leading additive manufacturing conference, in Frankfurt, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005056/en/ The Shop System™, the world’s first metal binder jetting system designed for machine shops and metal job shops, starting at $150,000. (Photo: Business Wire) Offering the most cost-effective solution in the industry starting at $150,000, this high-speed, single-pass print engine introduces high-quality binder jetting to an entirely new

Experience the World of Interconnected Security on IDEMIA’s Booth at Milipol Paris (november 19-22, 2019)19.11.2019 09:44:00 CETPress release

Today, more than ever before, new digital and biometric technologies represent the future of public security to provide trusted and reliable security solutions based on identity, and to maintain at the same time efficiency and convenience that ease citizens’ lives. At Milipol Paris, IDEMIA will showcase its cutting-edge technologies in three fields so that visitors can experience the whole future of security. Securing major events Thanks to its 40 years of strong relationships with the world’s leading law enforcement agencies and governments, IDEMIA has developed an in-depth understanding of the processes and procedures involved to ensure security at major events. The company not only provides the most innovative, biometric technologies – it also ensures interoperability of systems for a smooth and efficient running of events. IDEMIA’s innovative and intelligent systems use highly accurate algorithms integrated in its video and intelligence analytics to help secure major event, critica

Valamis’ Global Survey Reveals the State of L&D in 201919.11.2019 09:00:00 CETPress release

Valamis, the global leader in digital learning technologies and workforce development, published results from the “Learning and Development in Organizations in 2019 Report”, which combines key results from national surveys executed in the US, Germany, and Finland between April and July of 2019. The importance of learning and development for the organization’s success is recognized throughout each country surveyed; 96 percent of all respondents stated that it is very important or of medium importance to continually update the knowledge and skills of employees. The country comparison reveals that learning and development have reached greater maturity in the US when compared with Germany and Finland. Digital learning environments are more widely in use in organizations, and they are being updated to newer platforms more often. The top two challenges for learning and development were the same in all countries: No time and no money, and the third challenge was not the right tools in use (th

conova deploys ADVA OLS solution for highly secure DCI connectivity19.11.2019 08:00:00 CETPress release

ADVA (FSE: ADV) today announced that conova communications is using its technology for secure, high-capacity transport between data centers. conova, one of Austria’s leading IT service providers, has deployed the ADVA FSP 3000 open line system (OLS) with ConnectGuard™ Optical encryption in response to booming demand from business customers for reliable and protected cloud services. The fully redundant infrastructure supports 100Gbit/s Carrier Ethernet as well as 32Gbit/s Gen 6 Fibre Channel, a key requirement for the most advanced enterprise storage services. Featuring ADVA ALM fiber assurance technology, the new DCI network also enables rapid repair times and improves performance. The solution was designed and implemented by ADVA’s Elite partner dacoso, a German IT service provider focusing on connectivity, cyber defense and virtual networking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005076/en/ ADVA's technolog